Vivos Therapeutics Reports 76% Revenue Growth to $6.8 Million, Faces Increased Net Loss

Vivos Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated total revenue of approximately $6.8 million for the third quarter, marking a 76% increase from $3.9 million in the same period last year. This growth was primarily driven by a substantial rise in service revenue, which reached $4.6 million, largely attributed to the operations of The Sleep Center of Nevada (SCN), acquired in June 2025. Product revenue also saw an increase, totaling $2.2 million, compared to $2.0 million in the prior year.

In terms of profitability, Vivos reported a net loss of $5.4 million for the third quarter, up from a loss of $2.6 million in the same quarter of 2024. For the nine months ended September 30, 2025, the net loss was $14.3 million, compared to $8.3 million for the same period in 2024. The increase in losses was attributed to higher operating expenses, particularly in general and administrative costs, which rose to $7.9 million from $4.5 million year-over-year, largely due to the integration of SCN and associated operational costs.

Strategically, Vivos has shifted its business model from relying on its legacy VIP enrollment system to focusing on acquisitions and partnerships with sleep centers. The acquisition of SCN, which included a cash payment of $6 million and the issuance of 607,287 shares of common stock, is a key component of this strategy. The company aims to leverage SCN's existing operations to enhance its service offerings and revenue streams. As of September 30, 2025, Vivos had approximately $3.1 million in cash and cash equivalents, which raises concerns about its ability to fund operations without additional financing.

Operationally, Vivos has reported a significant increase in customer engagement, with SCN generating $2.2 million in sleep testing services and $1.3 million from treatment centers in the third quarter. The company is actively working to expand its operational capacity to meet growing patient demand, with plans to deploy additional teams to enhance service delivery. However, challenges remain, including the need for further financing to support ongoing operations and strategic initiatives.

Looking ahead, Vivos is focused on integrating SCN into its operations and exploring additional acquisition opportunities to expand its market presence. The company is also evaluating its strategic alliances to drive revenue growth. Despite the current financial challenges, Vivos remains optimistic about its long-term prospects, contingent on successful execution of its new business model and operational strategies.